Table 5 Sensitivity of the stool DNA test targeting methylated SDC2 in different characteristics of CRC patients
| Â | SDC2-Combine A&B Sensitivity (95% CI) | SDC2-A Sensitivity (95% CI) | SDC2-B Sensitivity (95% CI) | P value |
|---|---|---|---|---|
Gender | ||||
Male | 86.00% (73.50–93.36%) | 82.00% (68.98–90.46%) | 84.00% (71.22–91.93%) | 0.862 |
Female | 88.46% (76.66–94.97%) | 84.62% (72.21–92.26%) | 86.54% (74.42–93.63%) | 0.848 |
Age | ||||
 < 35 | 100.00% (38.25–100.00%) | 100.00% (38.25–100.00%) | 100.00% (38.25–100.00%) | / |
35–45 | 70.00% (39.23–89.67%) | 70.00% (39.23–89.67%) | 70.00% (39.23–89.67%) | 1.000 |
46–55 | 92.31% (64.58–99.99%) | 84.62% (56.54–96.90%) | 76.92% (49.06–92.50%) | 0.554 |
 > 55 | 88.16% (78.78–93.86%) | 84.21% (74.24–90.89%) | 88.16% (78.78–93.86%) | 0.708 |
Clinical stage | ||||
0 | 50.00% (15.00–85.00%) | 50.00% (15.00–85.00%) | 50.00% (15.00–85.00%) | 1.000 |
I | 90.91% (60.09–99.99%) | 90.91% (60.09–99.99%) | 90.91% (60.09–99.99%) | 1.000 |
II | 85.71% (67.89–94.92%) | 85.71% (67.89–94.92%) | 82.14% (63.94–92.59%) | 0.913 |
III | 88.24% (72.78–95.93%) | 82.35% (66.11–92.03%) | 88.24% (72.78–95.93%) | 0.718 |
IV | 100.00% (29.02–100.00%) | 100.00% (29.02–100.00%) | 100.00% (29.02–100.00%) | / |
Not determined | 91.30% (72.03–98.75%) | 82.61% (62.26–93.63%) | 86.96% (67.03–96.31%) | 0.682 |